Printer Friendly

CANGUARD AND DEPRENYL RESEARCH LAWSUIT ADJOURNED TODAY; NO RESTRICTIONS IMPOSED ON CANGUARD

 CANGUARD AND DEPRENYL RESEARCH LAWSUIT ADJOURNED TODAY;
 NO RESTRICTIONS IMPOSED ON CANGUARD
 VANCOUVER, British Columbia, March 16 /PRNewswire/ -- Canguard Health Technologies Inc. (Vancouver: CGD) announced that its court case with Deprenyl Research Ltd. (NASDAQ: DEPLF, Toronto: DEP) was adjourned today owing to insufficient time for the matter to be heard by the court. The date for reconvening the action is to be set in the next few days and is expected to be some time next month. In ordering an adjournment today the presiding judge did not impose any terms restricting the activities of the Canguard Group. The previous restrictions consented to by the Canguard Group were in force until the matter was returned to Court today. The Canguard Group will continue the development of its product, PARKINYL (deprenyl), and is confident that it will be absolved of any patent infringement allegations during subsequent court proceedings.
 -0- 03/16/92
 /CONTACT: John B. Armstrong, president of Canguard Health Technologies, 604-682-1777/
 (DEPLF DEP. CGD.) CO: Canguard Health Technologies Inc.; Deprenyl Research Ltd. ST: British Columbia IN: HEA SU:


EH -- LA033 -- 8506 03/16/92 17:21 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 16, 1992
Words:186
Previous Article:HEALTHRIGHT LEGISLATION, SEPARATING FACT FROM MYTH
Next Article:WHERE'S THE BEEF? EL POLLO LOCO HAS THE ANSWER; TRENDSETTER IN HEALTHFUL FAST FOOD REVERSES ANOTHER TREND, ADDS STEAK PRODUCTS
Topics:


Related Articles
CANGUARD HEALTH TECHNOLOGIES INC. RESPONDS TO COMMENTS ON DEPRENYL RESEARCH LTD. PRESS RELEASE
CANGUARD HEALTH TECHNOLOGIES INC. RESPONDS TO LAWSUIT ANNOUNCED IN PRESS ON DEC. 3
CANGUARD HEALTH TECHNOLOGIES ANNOUNCES LAWSUIT UPDATE
DEPRENYL ADJOURNS APPLICATION FOR INJUNCTION
CANGUARD HEALTH TECHNOLOGIES ADJOURNMENT AGREEMENT
CANGUARD HEALTH TECHNOLOGIES RESPONSE TO DEPRENYL RELEASE
CANGUARD ANNOUNCES PRIVATE PLACEMENT AND APPOINTMENT OF FISCAL AGENT
CANGUARD SERVES NOTICE OF MOTION, FINAL AFFIDAVITS ON DEPRENYL RESEARCH; ANNOUNCES NEW BUSINESS DEVELOPMENTS
CANGUARD HEALTH TECHNOLOGIES INC. RELEASES DETAILS OF ANNUAL REPORT TO SHAREHOLDERS
DEPRENYL RESEARCH ANNOUNCES FINAL PROSPECTUS OF BONE HEALTH INC.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters